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Supplemental Materials 
 
Supplementary Figure 1. Frequency of DNA gains (up) and losses (down) observed in seven ALCL cell 
lines [five derived from ALK(+), one from ALK(-) and one from cutaneous ALCL]. Red (up) represents 
gains and blue (down) represents losses. X-axis, chromosome localization and physical mapping; Y-axis, 
proportion of cases showing the aberrations. 
 
 
Supplementary Figure 2. Validation of BLIMP1 deletion. FISH analysis has been performed for 
PRDM1 gene deletion on all ALCL cell lines and three clinical specimens previously analyzed through 
the Affymetrix SNP6.0 platforms. Karpas299, SUDHL1 and ALK(-) clinical specimen 2475/05 pictures 
are reported as example.	  Orange: PRDM1 gene locus (134 E15);	  Green: Cep 6 (RP11-164C22). 
 
	  
Figure S3. PRDM1 is a tumor suppressor gene in other in vitro models of ALCL. (A) BLIMP1 
protein level after infection with empty vector (pWPI) or vector for BLIMP1 re-expression (pWPI-HA-
BLIMP1) in JB6 and SUDHL1 ALK(+) cell lines. (B) Growth curve after infection for JB6 and SUDHL1 
cell lines, cells counted at day 2, 3, 4 after infection. (C) Percentage of GFP positive cells after infection 
at day 2, 3 and 4 in JB6 and SUDHL1 cell lines. (D) Percentage of dead cells after infection at day 2, 3 
and 4 in JB6 and SUDHL1 cell lines. 
 
Supplementary Figure 4. Kaplan-Meier graph showing OS in systemic ALCL according to the 
presence of PRDM1 inactivation and/or TP53 locus loss. X-axis, months; Y-axis, percentage of alive 
patients. 
 
Supplementary Table 1. Primers used for DNA sequencing or real-time PCR. 
	  
Supplementary Table 2. Clinical characteristics of the ALCL series. 
	  
Supplementary Table 3. Significant regions affected by DNA gains and losses in ALCL, as estimated 
using the GISTIC algorithm.  
	  
Supplementary Table 4. Significant regions affected by DNA gains and losses in ALK-ALCL, as 
estimated using the GISTIC algorithm.  
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Supplementary Figure 1. Frequency of DNA gains (up) and losses (down) observed in seven ALCL cell 
lines [five derived from ALK(+), one from ALK(-) and one from cutaneous ALCL]. Red (up) represents 
gains and blue (down) represents losses. X-axis, chromosome localization and physical mapping; Y-axis, 






Supplementary Figure 2. Validation of BLIMP1 deletion. FISH analysis has been performed for 
PRDM1 gene deletion on all ALCL cell lines and three clinical specimens previously analyzed through 
the Affymetrix SNP6.0 platforms. Karpas299, SUDHL1 and ALK(-) clinical specimen 2475/05 pictures 
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Figure S3. PRDM1 is a tumor suppressor gene in other in vitro models of ALCL. (A) BLIMP1 
protein level after infection with empty vector (pWPI) or vector for BLIMP1 re-expression (pWPI-HA-
BLIMP1) in JB6 and SUDHL1 ALK(+) cell lines. (B) Growth curve after infection for JB6 and SUDHL1 
cell lines, cells counted at day 2, 3, 4 after infection. (C) Percentage of GFP positive cells after infection 
at day 2, 3 and 4 in JB6 and SUDHL1 cell lines. (D) Percentage of dead cells after infection at day 2, 3 
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Supplementary Figure 4. Kaplan-Meier graph showing OS in systemic ALCL according to the 
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Supplementary Table 1. Primers used for DNA sequencing or real-time PCR. 
 
Application Target Primer FW (5-‘…-3’) Primer REV (5-‘…-3’) 
Mutational analysis PRDM1-ex1 TGACGCCAAACACATGTTAAA GTTCCAGCTCACACTCGTCA 
Mutational analysis PRDM1-ex21 TATACGGCTTCTTGGCTCTT AGGAACAGTTGAAGGCTGG 
Mutational analysis PRDM1-ex31 AGATGGTCTCCCCCTATGGT AAGCAAGCAACAAACTGTTTC 
Mutational analysis PRDM1-ex41 GCCCTGATTTCTGCTGATTC GTCCCTAGCTTAAGCCACCT 
Mutational analysis PRDM1-ex1b TAGATGTTCATCCCGTTCTGA ACTTGAGAATGACCAAAATG 
Mutational analysis PRDM1-ex51 TTGAGTGAGTGGCCCAGAG AGGGAAGTCACTTGTCCAAA 
Mutational analysis PRDM1-ex61 AAACTCCCTGCTAGCCTGTG GCCATCTCAAGTCATCAGCA 
Mutational analysis PRDM1-ex71 CACAAGGAGGCTTCTCACCT GATTTCAGTAACTTTGGAGTT 
Mutational analysis TP53-ex42 TCCTCTGACTGCTCTTTTCAC TGAAGTCTCATGGAAGCCAG 
Mutational analysis TP53-ex52  GTTTCTTTGCTGCCGTCTTC AGCAATCAGTGAGGAATCAG 
Mutational analysis TP53-ex62 TCTGATTCCTCACTGATTGCTC CCACTGACAACCACCCTTAAC 
Mutational analysis TP53-ex72 TCATCTTGGGCCTGTGTTATC AGTGTGCAGGGTGGCAAG 
Mutational analysis TP53-ex82 AGGACCTGATTTCCTTACTGCC ATAACTGCACCCTTGGTCTCC 
Methylation analyisis PRDM1-meth TTAGTAAATTTGGGGGAAAGTTTTG TTAGTAAATTTGGGGGAAAGTTTTG 
Real time PCR PRDM1 ACATGACCGGCTACAAGACC GGCATTCATGTGGCTTTTCT 
Real time PCR FGG TGCATTAAGAGTGGAACTGGAA TGTTAGGCGGTACTTGTCAG 
Real time PCR SERPINA3 GTTCAGAGAGATAGGTGAGC CTGGTGAAGGCTTCCTCAAT 
Real time PCR SHIP1 CCCTGCAAGAAATCACCAGT ATCCGGTTCTCGTGCTCAG  
Real time PCR PMAIP1 GAGATGCCTGGGAAGAAGG TTCTGCCGGAAGTTCAGTTT 
Real time PCR GAPDH CGACCACTTTGTCAAGCTCA CCCTGTTGCTGTAGCCAAAT 
1. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell 
lymphoma. J Exp Med. 2006;203(2):311-317. 
2. Rassidakis GZ, Thomaides A, Wang S, et al. p53 gene mutations are uncommon but p53 is commonly expressed in 
anaplastic large-cell lymphoma. Leukemia. 2005;19(9):1663-1669. 
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Supplementary Table 2. Clinical characteristics of the ALCL series a. 
	  
 ALK-   ALK+   
 n Valid Percentage n Valid Percentage 
median age (range) 60 (13-83) 28  
21.5  
(8-68) 30  
Male/Female 17/11 28  16/14 30  
Stage       
I 3 14 21.4% 3 18 16.7% 
II 6 14 42.8% 3 18 16.7% 
III 1 14 7.2% 4 18 22.2% 
IV 4 14 28.6% 8 18 44.4% 
B symptoms       
Yes 6 9 66.7% 9 15 60% 
No 3 9 33.3% 6 15 40% 
Elevated LDH       
Yes 6 10 60% 10 18 55.6% 
No 4 10 40% 8 18 44.4% 
BM involvement       
Yes 0 13 0% 5 18 27.8% 
No 13 13 100% 13 18 72.2% 
Performance status       
0 3 8 37.5% 7 12 58.3% 
1 4 8 50% 1 12 8.3% 
2 1 8 12.5% 4 12 33.4% 
Therapy       
CHOP regimen 7 13 53.8% 13 22 59.1% 
no CHOP regimen 6 13 46.2% 9 22 40.9% 
	  
a LDH, lactate dehydrogenase; BM, bone marrow; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone. 
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Supplementary Table 3. Significant regions affected by DNA gains and losses in ALCL, as 
estimated using the GISTIC algorithm.  
	  
Lesions	   Cytoband	   Frequency	   Start*	   Size*	   q-­‐value	   Residual	  q-­‐value	   Candidate	  gene	  
Gains	   	   	   	   	   	   	   	  
	   9p24.1	  	  	   11%	   5,51E+06	   2,64E+06	   0,23624	   0,23624	   NCAM2	  
	   3p26.3	  	  	   6%	   1,67E+06	   1,14E+05	   0,23624	   0,23624	   	  
	   15q11.2	  	   7%	   2,53E+07	   3,74E+04	   0,23624	   0,23624	   IPW	  
	   20q11.22	   6%	   3,28E+07	   2,69E+05	   0,23624	   0,23624	   ASIP,	  AHCY,	  ITCH,	  MIR644	  
	   11p13	  	  	  	   5%	   3,48E+07	   6,87E+05	   0,23624	   0,23624	   APIP,	  PDHX,	  CD44	  
	   13q31.3	  	   3%	   8,90E+07	   4,22E+06	   0,23624	   0,23624	   MIR17HG	  
	   15q25.2	  	   3%	   8,45E+07	   2,85E+04	   0,23624	   0,23624	   ADAMTSL3	  
Losses	   	   	   	   	   	   	   	  
	   17p13.1	  	   25%	   6094336	   1,62E+06	   0,081305	   0,0099598	   TP53	  
	   6q21	  	  	  	  	   17%	   94817995	   2,12E+07	   4,68E-­‐11	   2,81E-­‐10	   ATG5,	  PRDM1	  
	   13q32.3	  	   16%	   93231989	   1,52E+07	   0,0025428	   0,011625	   	  
	   14q11.2	  	   16%	   22185014	   1,29E+06	   6,57E-­‐08	   1,88E-­‐07	   TCRA,	  TRAC	  
	   16q23.2	  	   16%	   78750889	   4,46E+03	   1	   0,1503	   WWOX	  
	   12q24.31	   13%	   121569998	   5,68E+05	   0,052865	   0,08445	   	  
	   13q21.31	   13%	   62409809	   3,97E+06	   0,0092452	   0,040311	   	  
	   13q31.1	  	   13%	   82365728	   6,66E+06	   0,052865	   0,098264	   SLITRK1,	  SLITRK6	  
	   1p13.2	  	  	   13%	   108240651	   1,09E+07	   0,026836	   0,014931	   	  
	   13q21.2	  	   11%	   60450644	   2,02E+05	   1	   0,18826	   DIAPH3	  
	   12q12	  	  	  	   9%	   44431029	   3,90E+05	   0,57913	   0,11838	   TMEM117	  
	   15q26.1	  	   9%	   89159161	   4,58E+04	   0,052865	   0,08445	   AEN,	  ISG20	  
	   2q37.3	  	  	   8%	   240125114	   1,50E+05	   0,026836	   0,041884	   HDAC4,	  MIR4269	  
	   18q22.1	  	   5%	   65059883	   3,95E+05	   0,0067821	   0,013671	   DSEL	  
	   20q13.13	   5%	   48907930	   7,76E+04	   0,048594	   0,069286	   	  
	   7q31.1	  	  	   5%	   110681611	   8,13E+04	   0,14064	   0,18826	   IMMP2L	  
	   1q32.1	  	  	   3%	   198580256	   3,31E+05	   0,026836	   0,041884	   PTPRC	  
	   14q23.1	  	   3%	   61926178	   1,41E+03	   1	   0,18826	   PRKCH	  
	   1p31.3	  	  	   3%	   66726940	   9,79E+04	   0,081305	   0,1503	   PDE4B	  
	   21q21.1	  	   2%	   22619036	   3,63E+03	   1	   0,11838	   NCAM2	  
	  
* Numbering according to Genome Reference Consortium Human Build 37 (GRCh37) (hg19). 
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Supplementary Table 4. Significant regions affected by DNA gains and losses in ALK-ALCL, 
as estimated using the GISTIC algorithm.  
 
Lesions	   Cytoband	   Frequency	   Start*	   Size*	   q-­‐value	   Residual	  q-­‐value	   Candidate	  Gene	  
Gains	   	   	   	   	   	   	   	  
	   20q11.22	   12%	   3,28E+07	   2,69E+05	   0,22719	   0,22719	   ASIP,	  AHCY,	  ITCH,	  MIR644	  
	   11p13	  	  	  	   6%	   3,48E+07	   6,87E+05	   0,22719	   0,22719	   APIP,	  PDHX,	  CD44	  
	   13q31.3	  	   6%	   8,90E+07	   4,22E+06	   0,22719	   0,22719	   MIR17HG	  
Losses	   	   	   	   	   	   	   	  
	   17p13.1	  	   42%	   7,47E+06	   1,06E+04	   0,99208	   0,1585	   TP53	  
	   14q11.2	  	   39%	   2,22E+07	   1,29E+06	   6,74E-­‐06	   3,35E-­‐05	   TCRA,	  TRAC	  
	   6q21	  	  	  	  	   33%	   9,48E+07	   1,86E+07	   1,43E-­‐08	   8,94E-­‐08	   ATG5,	  PRDM1	  
	   12q24.31	   27%	   1,22E+08	   5,68E+05	   0,021862	   0,039734	   	  
	   1p13.2	  	  	   24%	   9,85E+07	   2,19E+07	   0,0095216	   0,0063173	   	  
	   13q21.31	   24%	   6,24E+07	   3,97E+06	   0,003499	   0,066829	   	  
	   13q21.33	   24%	   6,64E+07	   7,05E+06	   0,0010479	   0,25555	   PCDH9,	  KHLH1	  
	   13q33.1	  	   24%	   9,32E+07	   1,52E+07	   0,003499	   0,047195	   SLITRK1,	  SLITRK6	  
	   13q21.2	  	   21%	   6,05E+07	   2,02E+05	   0,99208	   0,14511	   DIAPH3	  
	   13q31.1	  	   21%	   8,24E+07	   6,59E+06	   0,021862	   0,091229	   	  
	   20p13	  	  	  	   18%	   7,35E+04	   1,93E+03	   0,1217	   0,21329	   	  
	   20q13.13	   18%	   4,89E+07	   4,00E+08	   0,019672	   0,039734	   	  
	   4q22.2	  	  	   15%	   9,40E+07	   1,39E+04	   1	   0,21329	   GRID2	  
	   18q23	  	  	  	   15%	   6,51E+07	   7,06E+07	   0,021862	   0,039734	   	  
	   21q21.1	  	   6%	   2,26E+07	   3,63E+03	   1	   0,047195	   NCAM2	  
	  
* Numbering according to Genome Reference Consortium Human Build 37 (GRCh37) (hg19). 
	  
	  
	  
	  
	  
	  
